Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | GFER | P55789 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402945 | 0.83 | KDM4E (0.45) | KDM4ELMNAL3MBTL1GFERALDH1A1 | |
| SCHEMBL22535973 | 0.73 | TDP1 (0.43) | KDM4ELMNAL3MBTL1GFERHSD17B10 | |
| SCHEMBL16402390 | 0.70 | KDM4E (0.42) | KDM4ELMNAL3MBTL1GFERKDM4A | |
| SCHEMBL22535987 | 0.69 | TDP1 (0.46) | KDM4ELMNAL3MBTL1GFERPOLB | |
| SCHEMBL25930340 | 0.68 | EZH2 (0.48) | — | |
| SCHEMBL22535990 | 0.68 | TDP1 (0.44) | KDM4ELMNAL3MBTL1GFERPOLB | |
| SCHEMBL12906668 | 0.66 | KDM4A (0.43) | KDM4ELMNAL3MBTL1GFERHSD17B10 | |
| SCHEMBL16120372 | 0.66 | EZH2 (0.51) | — | |
| SCHEMBL11400715 | 0.66 | KDM4E (0.36) | KDM4ELMNAL3MBTL1GFERHSD17B10 | |
| SCHEMBL21500329 | 0.65 | EZH2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150764-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-12-11 | — | — | US | disclosed |
| EP-3022184-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-07-07 | — | — | US | disclosed |
| EP-3022184-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015010049-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | KDM4E 711/4885LMNA 1888/4885L3MBTL1 2668/4885 |
| US-10150764-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | KDM4E 711/4885LMNA 1888/4885L3MBTL1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.